NovaBay Pharmaceuticals To Present At The BIO International Convention

By June 16, 2008

Jack O’Reilly, Sr. VP of Corp. and Business Development of NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY), a clinical stage biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial, fungal, and viral infections, will present at the BIO International convention in San Diego, California, on June 18, 2008 at 1:30PT. The BIO International Convention (BIO) is a symposium including leading pharmaceutical and biotechnology companies presenting to institutional investors, portfolio managers, analysts, and the media, to discuss emerging trends in the sector.

Mr. O’Reilly will provide a corporate overview and review NovaBay’s two-pronged business development strategy of partnering with premiere healthcare companies for certain indications, while retaining exclusive rights to product development candidates in the areas of hospital infections, catheter-associated urinary tract infections, and dermatology. NovaBay has a collaboration agreement with the leading eye care company in the world, Alcon Laboratories, Inc., to research, develop, and commercialize the company’s Aganocide® compounds to treat eye, ear, and sinus infections, as well as develop the next generation contact lens solution. NovaBay has also partnered with Kinetic Concepts, Inc. (KCI), to develop an anti-infective solution for use with KCI’s wound healing system. NovaBay has also recently announced positive results from a Phase IIa study of AgaNase™ for the nasal decolonization of Staph, including MRSA. The company is also developing product candidate opportunities for the dermatology market, details of which Mr. O’Reilly will provide during the presentation.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide® compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including resistant bacteria such as MRSA. NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in the eye, ear and sinus, and in contact lens solutions. The company also has a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay’s NeutroPhase product in wound care applications.
NovaBay™, Aganocide®, AgaNase™, and NeutroPhase™ are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.

Forward-Looking Statements
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Contact:

Investors:
NovaBay Pharmaceuticals Contacts
Theresa Granados
510-899-8870
Head of Investor Relations
tgranados@novabaypharma.com

or

The Investor Relations Group
Investor Relations:
Adam Holdsworth / Erica Ruderman
212-825-3210
or
Media Relations:
Janet Vasquez / Laura Colontrelle
212-825-3210

TOP